Novel immunotherapies for psoriasis (Q34500946)

2 August 2017

1 reference

title

Novel immunotherapies for psoriasis (English)

1 reference

2 August 2017

1 reference

2

Hans-Dieter Volk

1 reference

2 August 2017

Khusru Asadullah

1

1 reference

PubMed ID

11801454

2 August 2017

Wolfram Sterry

series ordinal

3

1 reference

2 August 2017

1 January 2002

1 reference

2 August 2017

1 reference

2 August 2017

23

1 reference

2 August 2017

1

1 reference

2 August 2017

47-53

1 reference

A pharmacoeconomic analysis of topical therapies for patients with mild-to-moderate stable plaque psoriasis: a US study.

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Severe combined immunodeficiency mouse-human skin chimeras: a unique animal model for the study of psoriasis and cutaneous inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Psoriasis: the plot thickens....

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Lymphocyte activation in the pathogenesis of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Is psoriasis a neuroimmunologic disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Investigation on a novel and specific leukotriene B4 receptor antagonist in the treatment of stable plaque psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

VML 295 (LY-293111), a novel LTB4 antagonist, is not effective in the prevention of relapse in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Immunointervention in psoriasis with anti-CD4 antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

The effect of anti-CD4 monoclonal antibody treatment on immunopathological changes in psoriatic skin

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Anti-CD4 monoclonal antibody therapy in severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Psoriasis vulgaris treated successfully with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Interleukin-10 in cutaneous disorders: implications for its pathophysiological importance and therapeutic use.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Treatment of psoriasis with interleukin-10

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

The immunology of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2902119-6

7 January 2021

10.1016/S1471-4906(01)02119-6

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11801454